{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122816","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.266875+00:00","generated_at":"2026-05-30T03:39:04.784183+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PMV Pharma Q3 net loss $19.2M; cash runway to end 2026; Phase 2 enrollment on track","bullets":["Net loss $19.2M in Q3 2024 vs $16.6M Q3 2023; R&D spend rose to $16.9M on trial costs.","Cash $197.9M at Sep 30, 2024; provides expected runway to end of 2026.","Phase 2 PYNNACLE trial enrollment on track; >75% sites activated; interim analysis expected mid-2025.","Investigator-initiated Phase 1b of rezatapopt in AML/MDS with MD Anderson and MSKCC; enrollment planned Q1 2025.","Discontinued Phase 1b combination arm with pembrolizumab due to dose-limiting toxicities and limited benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122816","json":"https://secwatch.observer/filing/0000950170-24-122816.json","markdown":"https://secwatch.observer/filing/0000950170-24-122816.md","text":"https://secwatch.observer/filing/0000950170-24-122816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024122816/0000950170-24-122816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017024122816/pmvp-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:39:04.784183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}